The decision on whether or not to undergo the Prostate Specific Antigen Test (PSA) to screen for prostate cancer is very complex.
And the decision on what if any therapy to undergo once prostate cancer has been diagnosed is also very complex.
Below are some resources that can help a man make an informed decision about each of the above questions.
The U.S. Preventive Services Task Force recommended in Prostate Cancer: Screening
Release Date: May 2012:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
However, The USPTF is currently updating the above recommendation.
Here is a link to resources about the Prostate Cancer Screening Draft Recommendations
Here are the Draft Recommendations for Prostate Cancer Screening:
For Men 55 – 69
The decision about whether to be screened for prostate cancer should be an individual one. The USPSTF recommends that clinicians inform men ages 55 to 69 years about the potential benefits and harms of prostate-specific antigen (PSA)–based screening for prostate cancer. Screening offers a small potential benefit of reducing the chance of dying of prostate cancer. However, many men will experience potential harms of screening, including false-positive results that require additional workup, overdiagnosis and overtreatment, and treatment complications such as incontinence and impotence. The USPSTF recommends individualized decisionmaking about screening for prostate cancer after discussion with a clinician, so that each man has an opportunity to understand the potential benefits and harms of screening and to incorporate his values and preferences into his decision.
Men Aged 70 and older
The USPSTF recommends against PSA-based screening for prostate cancer in men age 70 years and older.
Draft Recommendation Statement Prostate Cancer: Screening From The U.S. Preventive Services Task Force:Current as of: April 2017
This opportunity for public comment expires on May 8, 2017 at 8:00 PM EST
Note: This is a Draft Recommendation Statement. This draft is distributed solely for the purpose of receiving public input. It has not been disseminated otherwise by the USPSTF. The final Recommendation Statement will be developed after careful consideration of the feedback received and will include both the Research Plan and Evidence Review as a basis.
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Prostate Cancer Screening (PDQ®)–Health Professional Version [Updated March 31, 2017.]
Prostate Cancer Treatment (PDQ®)–Health Professional Version From the National Cancer Institute of The National Institutes Of Health. [Updated March 31, 2017.]